Evidence for the use of pimavanserin in the treatment of Parkinson's disease psychosis.

摘要: Parkinson’s disease (PD) is a progressive neurodegenerative disorder with both motor and nonmotor symptoms (NMS), leading to significant morbidity caregiver burden. Psychosis common but under recognized by physicians. When present, it increases the patient’s risk of hospitalization nursing home placement Although atypical antipsychotic agent, clozapine, has been considered gold standard treatment, severe agranulocytosis in 0.38% patients more commonly milder leukopenia, resulting frequent blood testing, limit its use. Pimavanserin, 5HT2A receptor inverse agonist, shown reduce psychosis PD without worsening symptoms. It therefore welcome therapeutic option for this devastating NMS.